EEG Latent-Space Modeling for Antidepressant Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressant treatments for depression show only a small overall advantage over placebo, with clinical significance primarily in severe cases, and there is a need for objective measures to stratify depressed patients into those who benefit from antidepressants and those who do not.
Innovation Solution
A Sparse Electroencephalography Latent Space Regression (SELSER) computational model is used to analyze brain signals such as EEG, TMS-EEG, MEG, fMRI, and fNIRS data to identify antidepressant-responsive depression phenotypes by generating latent signals and predicting treatment outcomes, allowing for personalized treatment selection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antidepressant medications are used to treat depression, then treatment coverage is provided for depressed patients, but the overall advantage over placebo is small with clinical significance only in severe cases
Solution Approach 1:
The patent segments the heterogeneous depression population into distinct biological phenotypes or subtypes based on objective biological measures (genetic, neuroimaging, biomarker data). This segmentation allows identification of specific patient subgroups who are more likely to respond to antidepressant treatment, thereby improving treatment effectiveness for targeted populations rather than treating depression as a uniform condition.
Solution Approach 2:
The patent changes the parameters used for patient classification from subjective clinical symptoms to objective biological parameters (genetic markers, neuroimaging features, biomarker levels). This parameter transformation enables more precise prediction of treatment response and identifies biological phenotypes that differentiate responders from non-responders to antidepressant therapy.
2Adaptability or versatility
If clinical diagnosis of depression is based on heterogeneous biological phenotypes, then patient diversity is captured, but objective measures to stratify patients are lacking
Solution Approach 1:
The patent develops a multi-functional assessment framework that integrates multiple types of biological measures (genetic profiling, neuroimaging, biomarker analysis) into a unified system for predicting antidepressant response. This universal approach can accommodate diverse patient phenotypes and provides consistent objective measurement across different biological domains, improving both patient coverage and prediction accuracy.
Solution Approach 2:
The patent creates a composite biological profile for each patient by combining multiple types of biological data (genetic markers, neuroimaging features, biomarker levels) into an integrated assessment. This composite approach captures the complexity of heterogeneous depression phenotypes while providing a unified objective measure for treatment response prediction, thereby improving measurement precision across diverse patient populations.
3Ease of operation
If antidepressant treatment is applied to unselected depressed patients, then treatment accessibility is maintained, but the small overall advantage over placebo reduces clinical utility
Solution Approach 1:
The patent implements preliminary biological assessment (genetic testing, neuroimaging, biomarker measurement) before initiating antidepressant treatment to identify patients most likely to respond. This preliminary action stratifies patients into high-probability responder groups, ensuring that antidepressant treatment is directed toward patients who will benefit, thereby improving outcome predictability while maintaining a relatively simple treatment implementation process for selected patients.
Data Source
AI summary
Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.